ArticleJCO oncology practice2024
Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care.
Article in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework.JCO precision oncology · 2025Pooled it
- Pooled it
- Natural language processing to develop a standardized lexicon for precision medicine in oncology.Journal of managed care & specialty pharmacy · 2026Article
- Targeted Therapy, Immunotherapy, and Molecular Testing in Advanced Solid Tumors: A Medicare Analysis.Cancer medicine · 2026Observational
- Key considerations when assessing clinical utility for biomarker testing: A checklist.Journal of managed care & specialty pharmacy · 2026Article
- Clinical harm from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2026Article
- Ten Healthcare Delivery Trends and Their Measurement and Methodological Implications for Cancer Health Services Research.Health services research · 2026Article
- Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise ofFrontiers in immunology · 2026Review
- The patient journey and guideline-concordant care in colorectal cancer-is current practice enough?Frontiers in medicine · 2026Article
- Biomarker Testing Approaches, Treatment Selection, and Cost of Care Among Adults With Advanced Cancer.JAMA network open · 2025Article
- Assessing the Data Quality Dimensions of Surgical Oncology Cohorts in theJCO clinical cancer informatics · 2025Article
- ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team.American journal of clinical pathology · 2025Article
- Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non-Small Cell Lung Cancer.JCO precision oncology · 2025Article
- Towards precision care: Fluctuations in albumin and fibrinogen as noninvasive predictors of endoscopic outcomes in Crohn's disease.World journal of gastrointestinal endoscopy · 2025Article
- Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.Biomedicines · 2025Review
- Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.Future oncology (London, England) · 2024Article
- Evaluation of the ASPYRE-Lung targeted variant panel: a rapid, low-input solution for non-small cell lung cancer biomarker testing and experience from three independent sites.Translational lung cancer research · 2024Article
- Advancements in Biomarkers and Molecular Targets in Hematological Neoplasias.International journal of molecular sciences · 2024Article
- ASPYRE-Lung: validation of a simple, fast, robust and novel method for multi-variant genomic analysis of actionable NSCLC variants in FFPE tissue.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.